Timothy J Mcdonald

List of Publications by Year
in descending order

113 papers	5,220 citations	117625 34 h-index	95266 68 g-index
121 all docs	121 docs citations	121 times ranked	6616 citing authors

#	ARTICLE	IF	CITATIONS
1	Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn's disease: a prospective, multicentre, cohort study. The Lancet Gastroenterology and Hepatology, 2019, 4, 341-353.	8.1	431
2	Activating germline mutations in STAT3 cause early-onset multi-organ autoimmune disease. Nature Genetics, 2014, 46, 812-814.	21.4	411
3	HLA-DQA1*05 Carriage Associated With Development of Anti-Drug Antibodies to Infliximab and Adalimumab in Patients With Crohn's Disease. Gastroenterology, 2020, 158, 189-199.	1.3	249
4	The majority of patients with long-duration type 1 diabetes are insulin microsecretors and have functioning beta cells. Diabetologia, 2014, 57, 187-191.	6.3	240
5	The development and validation of a clinical prediction model to determine the probability of MODY in patients with young-onset diabetes. Diabetologia, 2012, 55, 1265-1272.	6.3	238
6	Infliximab is associated with attenuated immunogenicity to BNT162b2 and ChAdOx1 nCoV-19 SARS-CoV-2 vaccines in patients with IBD. Gut, 2021, 70, 1884-1893.	12.1	233
7	A Type 1 Diabetes Genetic Risk Score Can Aid Discrimination Between Type 1 and Type 2 Diabetes in Young Adults. Diabetes Care, 2016, 39, 337-344.	8.6	231
8	Islet autoantibodies can discriminate maturity‐onset diabetes of the young (MODY) from Type ƒ1 diabetes. Diabetic Medicine, 2011, 28, 1028-1033.	2.3	173
9	Systematic Population Screening, Using Biomarkers and Genetic Testing, Identifies 2.5% of the U.K. Pediatric Diabetes Population With Monogenic Diabetes. Diabetes Care, 2016, 39, 1879-1888.	8.6	172
10	Anti-SARS-CoV-2 antibody responses are attenuated in patients with IBD treated with infliximab. Gut, 2021, 70, 865-875.	12.1	153
11	Markers of β-Cell Failure Predict Poor Glycemic Response to GLP-1 Receptor Agonist Therapy in Type 2 Diabetes. Diabetes Care, 2016, 39, 250-257.	8.6	132
12	Maturity onset diabetes of the young: identification and diagnosis. Annals of Clinical Biochemistry, 2013, 50, 403-415.	1.6	131
13	Urinary C-Peptide Creatinine Ratio Is a Practical Outpatient Tool for Identifying Hepatocyte Nuclear Factor 1-α/Hepatocyte Nuclear Factor 4-α Maturity-Onset Diabetes of the Young From Long-Duration Type 1 Diabetes. Diabetes Care, 2011, 34, 286-291.	8.6	123
14	Population-Based Assessment of a Biomarker-Based Screening Pathway to Aid Diagnosis of Monogenic Diabetes in Young-Onset Patients. Diabetes Care, 2017, 40, 1017-1025.	8.6	111
15	Most People With Long-Duration Type 1 Diabetes in a Large Population-Based Study Are Insulin Microsecretors. Diabetes Care, 2015, 38, 323-328.	8.6	104
16	Type 1 diabetes defined by severe insulin deficiency occurs after 30 years of age and is commonly treated as type 2 diabetes. Diabetologia, 2019, 62, 1167-1172.	6.3	100
17	Studies of insulin and proinsulin in pancreas and serum support the existence of aetiopathological endotypes of type 1 diabetes associated with age at diagnosis. Diabetologia, 2020, 63, 1258-1267.	6.3	98
18	High-Sensitivity CRP Discriminates HNF1A-MODY From Other Subtypes of Diabetes. Diabetes Care, 2011, 34, 1860-1862.	8.6	90

#	Article	IF	Citations
19	The <i>HNF4A</i> R76W mutation causes atypical dominant Fanconi syndrome in addition to a β cell phenotype. Journal of Medical Genetics, 2014, 51, 165-169.	3.2	82
20	C-Peptide Decline in Type 1 Diabetes Has Two Phases: An Initial Exponential Fall and a Subsequent Stable Phase. Diabetes Care, 2018, 41, 1486-1492.	8.6	81
21	Precision Medicine in Type 2 Diabetes: Clinical Markers of Insulin Resistance Are Associated With Altered Short- and Long-term Glycemic Response to DPP-4 Inhibitor Therapy. Diabetes Care, 2018, 41, 705-712.	8.6	67
22	Urine C-Peptide Creatinine Ratio Is a Noninvasive Alternative to the Mixed-Meal Tolerance Test in Children and Adults With Type 1 Diabetes. Diabetes Care, 2011, 34, 607-609.	8.6	62
23	Stability and Reproducibility of a Single-Sample Urinary C-Peptide/Creatinine Ratio and Its Correlation with 24-h Urinary C-Peptide. Clinical Chemistry, 2009, 55, 2035-2039.	3.2	60
24	Commercial insulin immunoassays fail to detect commonly prescribed insulin analogues. Clinical Biochemistry, 2015, 48, 1354-1357.	1.9	55
25	Clinical Impact of Residual C-Peptide Secretion in Type 1 Diabetes on Glycemia and Microvascular Complications. Diabetes Care, 2021, 44, 390-398.	8.6	55
26	Latent Autoimmune Diabetes of Adults (LADA) Is Likely to Represent a Mixed Population of Autoimmune (Type 1) and Nonautoimmune (Type 2) Diabetes. Diabetes Care, 2021, 44, 1243-1251.	8.6	52
27	Random non‑fasting C‑peptide: bringing robust assessment of endogenous insulin secretion to the clinic. Diabetic Medicine, 2016, 33, 1554-1558.	2.3	50
28	Discovery of biomarkers for glycaemic deterioration before and after the onset of type 2 diabetes: rationale and design of the epidemiological studies within the IMI DIRECT Consortium. Diabetologia, 2014, 57, 1132-1142.	6.3	48
29	Antibody decay, T cell immunity and breakthrough infections following two SARS-CoV-2 vaccine doses in inflammatory bowel disease patients treated with infliximab and vedolizumab. Nature Communications, 2022, 13, 1379.	12.8	48
30	Predicting and elucidating the etiology of fatty liver disease: A machine learning modeling and validation study in the IMI DIRECT cohorts. PLoS Medicine, 2020, 17, e1003149.	8.4	47
31	Persistent C-peptide secretion in Type 1 diabetes and its relationship to the genetic architecture of diabetes. BMC Medicine, 2019, 17, 165.	5.5	43
32	Diagnostic performance of a faecal immunochemical test for patients with low-risk symptoms of colorectal cancer in primary care: an evaluation in the South West of England. British Journal of Cancer, 2021, 124, 1231-1236.	6.4	41
33	Lipoprotein composition in HNF1A-MODY: Differentiating between HNF1A-MODY and Type 2 diabetes. Clinica Chimica Acta, 2012, 413, 927-932.	1.1	39
34	EDTA Improves Stability of Whole Blood C-Peptide and Insulin to Over 24 Hours at Room Temperature. PLoS ONE, 2012, 7, e42084.	2.5	39
35	Adalimumab and Infliximab Impair SARS-CoV-2 Antibody Responses: Results from a Therapeutic Drug Monitoring Study in 11 422 Biologic-Treated Patients. Journal of Crohn's and Colitis, 2022, 16, 389-397.	1.3	39
36	Beta cell function and ongoing autoimmunity in long-standing, childhood onset type 1 diabetes. Diabetologia, 2016, 59, 2722-2726.	6.3	37

#	Article	IF	Citations
37	A Type 1 Diabetes Genetic Risk Score Can Identify Patients With GAD65 Autoantibodyâ€"Positive Type 2 Diabetes Who Rapidly Progress to Insulin Therapy. Diabetes Care, 2019, 42, 208-214.	8.6	35
38	A type 1 diabetes genetic risk score can discriminate monogenic autoimmunity with diabetes from early-onset clustering of polygenic autoimmunity with diabetes. Diabetologia, 2018, 61, 862-869.	6.3	33
39	Urine Câ€peptide creatinine ratio is an alternative to stimulated serum Câ€peptide measurement in lateâ€onset, insulinâ€treated diabetes. Diabetic Medicine, 2011, 28, 1034-1038.	2.3	32
40	Persistent Câ€peptide is associated with reduced hypoglycaemia but not HbA$_{1c}$ in adults with longstanding Type 1 diabetes: evidence for lack of intensive treatment in UK clinical practice?. Diabetic Medicine, 2019, 36, 1092-1099.	2.3	32
41	Faecal calprotectin effectively excludes inflammatory bowel disease in 789 symptomatic young adults with/without alarm symptoms: a prospective UK primary care cohort study. Alimentary Pharmacology and Therapeutics, 2018, 47, 1103-1116.	3.7	31
42	Random non-fasting C-peptide testing can identify patients with insulin-treated type 2 diabetes at high risk of hypoglycaemia. Diabetologia, 2018, 61, 66-74.	6.3	30
43	Home urine C-peptide creatinine ratio testing can identify type 2 and MODY in pediatric diabetes. Pediatric Diabetes, 2012, 14, n/a-n/a.	2.9	29
44	Validation of a singleâ€sample urinary Câ€peptide creatinine ratio as a reproducible alternative to serum Câ€peptide in patients with Type 2 diabetes. Diabetic Medicine, 2012, 29, 90-93.	2.3	29
45	Hypoglycaemia following diabetes remission in patients with 6q24 methylation defects: expanding the clinical phenotype. Diabetologia, 2013, 56, 218-221.	6.3	24
46	Type 1 diabetes can present before the age of 6Âmonths and is characterised by autoimmunity and rapid loss of beta cells. Diabetologia, 2020, 63, 2605-2615.	6.3	24
47	Discovery of biomarkers for glycaemic deterioration before and after the onset of type 2 diabetes: descriptive characteristics of the epidemiological studies within the IMI DIRECT Consortium. Diabetologia, 2019, 62, 1601-1615.	6.3	22
48	A high-sensitivity electrochemiluminescence-based ELISA for the measurement of the oxidative stress biomarker, 3-nitrotyrosine, in human blood serum and cells. Free Radical Biology and Medicine, 2018, 120, 246-254.	2.9	20
49	The impact of insulin administration during the mixed meal tolerance test. Diabetic Medicine, 2012, 29, 1279-1284.	2.3	19
50	Fetal Macrosomia and Neonatal Hyperinsulinemic Hypoglycemia Associated With Transplacental Transfer of Sulfonylurea in a Mother With *KCNJ11*-Related Neonatal Diabetes. Diabetes Care, 2014, 37, 3333-3335.	8.6	19
51	Zinc Transporter 8 Autoantibodies (ZnT8A) and a Type 1 Diabetes Genetic Risk Score Can Exclude Individuals With Type 1 Diabetes From Inappropriate Genetic Testing for Monogenic Diabetes. Diabetes Care, 2019, 42, e16-e17.	8.6	19
52	The association between postprandial urinary Câ€peptide creatinine ratio and the treatment response to liraglutide: a multiâ€centre observational study. Diabetic Medicine, 2014, 31, 403-411.	2.3	18
53	Predictors of Recurrent Severe Hypoglycemia in Adults With Type 1 Diabetes and Impaired Awareness of Hypoglycemia During the HypoCOMPaSS Study. Diabetes Care, 2020, 43, 44-52.	8.6	18
54	The impact of gender on urine C-peptide creatinine ratio interpretation. Annals of Clinical Biochemistry, 2012, 49, 363-368.	1.6	17

#	Article	IF	Citations
55	Urine C-peptide creatinine ratio can be used to assess insulin resistance and insulin production in people without diabetes: an observational study. BMJ Open, 2013, 3, e003193.	1.9	17
56	Profiles of Glucose Metabolism in Different Prediabetes Phenotypes, Classified by Fasting Glycemia, 2-Hour OGTT, Glycated Hemoglobin, and 1-Hour OGTT: An IMI DIRECT Study. Diabetes, 2021, 70, 2092-2106.	0.6	17
57	Processes Underlying Glycemic Deterioration in Type 2 Diabetes: An IMI DIRECT Study. Diabetes Care, 2021, 44, 511-518.	8.6	16
58	Assessment of endogenous insulin secretion in insulin treated diabetes predicts postprandial glucose and treatment response to prandial insulin. BMC Endocrine Disorders, 2012, 12, 6.	2.2	14
59	Urinary C€peptide creatinine ratio detects absolute insulin deficiency in Type 2 diabetes. Diabetic Medicine, 2013, 30, 1342-1348.	2.3	13
60	Investigating hyperkalaemia in adults. BMJ, The, 2015, 351, h4762.	6.0	13
61	Current laboratory requirements for adrenocorticotropic hormone and renin/aldosterone sample handling are unnecessarily restrictive. Clinical Medicine, 2017, 17, 18-21.	1.9	13
62	Type 1 diabetes genetic risk score discriminates between monogenic and Type 1 diabetes in children diagnosed at the age of <5 years in the Iranian population. Diabetic Medicine, 2019, 36, 1694-1702.	2.3	13
63	Screening for neonatal diabetes at day 5 of life using dried blood spot glucose measurement. Diabetologia, 2017, 60, 2168-2173.	6.3	12
64	The role of physical activity in metabolic homeostasis before and after the onset of type 2 diabetes: an IMI DIRECT study. Diabetologia, 2020, 63, 744-756.	6.3	12
65	Diagnostic Confusion? Repeat HbA1cfor the Diagnosis of Diabetes: Figure 1. Diabetes Care, 2014, 37, e135-e136.	8.6	11
66	Postexercise Glycemic Control in Type 1 Diabetes Is Associated With Residual Î²-Cell Function. Diabetes Care, 2020, 43, 2362-2370.	8.6	11
67	Reappearance of C-Peptide During the Third Trimester of Pregnancy in Type 1 Diabetes: Pancreatic Regeneration or Fetal Hyperinsulinism?. Diabetes Care, 2021, 44, 1826-1834.	8.6	11
68	Interleukin-1 antagonism in type 1 diabetes of long duration. Diabetes and Metabolism, 2016, 42, 453-456.	2.9	10
69	Exocrine pancreatic dysfunction is common in hepatocyte nuclear factor 1Î²-associated renal disease and can be symptomatic. CKJ: Clinical Kidney Journal, 2018, 11, 453-458.	2.9	10
70	Effect of the Holiday Season in Patients With Diabetes: Glycemia and Lipids Increase Postholiday, but the Effect Is Small and Transient. Diabetes Care, 2014, 37, e98-e99.	8.6	9
71	Patterns of postmeal insulin secretion in individuals with sulfonylurea-treated KCNJ11 neonatal diabetes show predominance of non-KATP-channel pathways. BMJ Open Diabetes Research and Care, 2019, 7, e000721.	2.8	9
72	Validating the positivity thresholds of drug€tolerant anti€infliximab and anti€adalimumab antibody assays. Alimentary Pharmacology and Therapeutics, 2021, 53, 128-137.	3.7	9

#	Article	IF	Citations
73	Cystatin C is not a good candidate biomarker for HNF1A-MODY. Acta Diabetologica, 2013, 50, 815-820.	2.5	8
74	Stability of urinary albumin and creatinine after 12 months storage at −20°C and −80°C. Practical Laboratory Medicine, 2019, 15, e00120.	1.3	8
75	Whole blood co-expression modules associate with metabolic traits and type 2 diabetes: an IMI-DIRECT study. Genome Medicine, 2020, 12, 109.	8.2	8
76	Strategies to identify individuals with monogenic diabetes: results of an economic evaluation. BMJ Open, 2020, 10, e034716.	1.9	8
77	Detection of C-Peptide in Urine as a Measure of Ongoing Beta Cell Function. Methods in Molecular Biology, 2016, 1433, 93-102.	0.9	7
78	The governance structure for data access in the DIRECT consortium: an innovative medicines initiative (IMI) project. Life Sciences, Society and Policy, 2018, 14, 20.	3.2	7
79	Enzyme-linked immunosorbent assays for monitoring TNF-alpha inhibitors and antibody levels in people with rheumatoid arthritis: a systematic review and economic evaluation. Health Technology Assessment, 2021, 25, 1-248.	2.8	7
80	Patient-led Remote IntraCapillary pharmacoKinetic Sampling (fingerPRICKS) for Therapeutic Drug Monitoring in patients with Inflammatory Bowel Disease. Journal of Crohn's and Colitis, 2022, 16, 190-198.	1.3	7
81	Post-load glucose subgroups and associated metabolic traits in individuals with type 2 diabetes: An IMI-DIRECT study. PLoS ONE, 2020, 15, e0242360.	2.5	7
82	Glycated haemoglobin measurements from UK Biobank are different to those in linked primary care records: implications for combining biochemistry data from research studies and routine clinical care. International Journal of Epidemiology, 2022, 51, 1022-1024.	1.9	7
83	Infliximab and adalimumab are stable in whole blood clotted samples for seven days at room temperature. Annals of Clinical Biochemistry, 2015, 52, 672-674.	1.6	6
84	The association between GAD65 antibody levels and incident Type 2 Diabetes Mellitus in an adult population: A meta-analysis. Metabolism: Clinical and Experimental, 2019, 95, 1-7.	3.4	6
85	Measurement of Peak C-Peptide at Diagnosis Informs Glycemic Control but not Hypoglycemia in Adults With Type 1 Diabetes. Journal of the Endocrine Society, 2021, 5, bvab127.	0.2	6
86	Mortality amongst children and adolescents with type 1 diabetes in sub-Saharan Africa: The case study of the Changing Diabetes in Children program in Cameroon. Pediatric Diabetes, 2022, 23, 33-37.	2.9	6
87	Preanalytical sample handling of venous blood: how to ensure your glucose measurement is accurate and reliable. Practical Diabetes, 2013, 30, 128-131.	0.3	5
88	Home Urine C-Peptide Creatinine Ratio Can Be Used to Monitor Islet Transplant Function: Figure 1. Diabetes Care, 2014, 37, 1737-1740.	8.6	5
89	Low IgE Is a Useful Tool to Identify STAT3 Gain-of-Function Mutations. Clinical Chemistry, 2016, 62, 1536-1538.	3.2	5
90	The challenge of diagnosing type 1 diabetes in older adults. Diabetic Medicine, 2020, 37, 1781-1782.	2.3	5

#	Article	IF	Citations
91	HbA1c performs well in monitoring glucose control even in populations with high prevalence of medical conditions that may alter its reliability: the OPTIMAL observational multicenter study. BMJ Open Diabetes Research and Care, 2021, 9, e002350.	2.8	5
92	Capturing the realâ€world benefit of residual Î²â€cell function during clinically important timeâ€periods in established Type 1 diabetes. Diabetic Medicine, 2022, 39, e14814.	2.3	5
93	Understanding <scp>antiâ€TNF</scp> treatment failure: does serum triiodothyronineâ€toâ€thyroxine (<scp>T3</scp>/<scp>T4</scp>) ratio predict therapeutic outcome to <scp>antiâ€TNF</scp> therapies in biologicâ€naÃ¯ve patients with active luminal Crohn's disease?. Alimentary Pharmacology and Therapeutics, 2022, 56, 783-793.	3.7	5
94	Primary care faecal calprotectin testing in children with suspected inflammatory bowel disease: a diagnostic accuracy study. Archives of Disease in Childhood, 2020, 105, 957-963.	1.9	4
95	Zinc transporter 8 autoantibody testing requires age-related cut-offs. BMJ Open Diabetes Research and Care, 2021, 9, e002296.	2.8	4
96	Dietary metabolite profiling brings new insight into the relationship between nutrition and metabolic risk: An IMI DIRECT study. EBioMedicine, 2020, 58, 102932.	6.1	3
97	A novel case of a raised testosterone and LH in a young man. Clinica Chimica Acta, 2011, 412, 1999-2001.	1.1	2
98	Clinical profiles of postâ€load glucose subgroups and their association with glycaemic traits over time: An IMIâ€DIRECT study. Diabetic Medicine, 2021, 38, e14428.	2.3	2
99	Parental experiences of a diagnosis of neonatal diabetes and perceptions of newborn screening for glucose: a qualitative study. BMJ Open, 2020, 10, e037312.	1.9	2
100	Proinsulin is stable at room temperature for 24 hours in EDTA: A clinical laboratory analysis (adAPT) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	2.5	2
101	Using highly sensitive C-reactive protein measurement to diagnose MODY in a family with suspected type 2 diabetes. BMJ Case Reports, 2012, 2012, bcr0120125612-bcr0120125612.	0.5	2
102	Type 1 Diabetes Patients With Different Residual Beta-Cell Function but Similar Age, HBA1c, and Cardiorespiratory Fitness Have Differing Exercise-Induced Angiogenic Cell Mobilisation. Frontiers in Endocrinology, 2022, 13, 797438.	3.5	2
103	Comment on: â€œDulaglutide treatment results in effective glycaemic control in latent autoimmune diabetes in adults (LADA): A postâ€hoc analysis of the AWARDâ€2, â^’4 and â^’5 trialsâ€• Diabetes, Obesity and Metabolism, 2018, 20, 1549-1550.	4.4	1
104	OP22 Antibody decay, T cell immunity and breakthrough infections following SARS-CoV-2 vaccination in infliximab- and vedolizumab-treated patients. Journal of Crohn's and Colitis, 2022, 16, i023-i025.	1.3	1
105	Response to Comment on: McDonald et al. High-Sensitivity CRP Discriminates HNF1A-MODY From Other Subtypes of Diabetes. Diabetes Care 2011;34:1860-1862. Diabetes Care, 2011, 34, e187-e187.	8.6	0
106	A cautionary tale: Unforeseen consequences of lean processing in a blood sciences laboratory. Clinical Biochemistry, 2016, 49, 1311-1312.	1.9	0
107	P196 Pre-treatment antibodies to infliximab and adalimumab are common but are not associated with anti-TNF treatment failure. Journal of Crohn's and Colitis, 2022, 16, i256-i256.	1.3	0
108	Response to Comment on Meek et al. Reappearance of C-Peptide During the Third Trimester in Type 1 Diabetes Pregnancy: Pancreatic Regeneration or Fetal Hyperinsulinism? Diabetes Care 2021;44:1826â€"1834. Diabetes Care, 2022, 45, e43-e44.	8.6	0

#	Article	IF	Citations
109	Title is missing!. , 2020, 17, e1003149.		0
110	Title is missing!. , 2020, 17, e1003149.		0
111	Title is missing!. , 2020, 17, e1003149.		0
112	Title is missing!. , 2020, 17, e1003149.		0
113	Title is missing!. , 2020, 17, e1003149.		0